MarketLens
Sign Up

Has Xeris Biopharma Reached an Inflection Point

5 months ago
SHARE THIS ON:

Has Xeris Biopharma Reached an Inflection Point

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•1 week ago

DexCom: The 15-Day Sensor Lowered The Cost Curve Before The Type 2 Wave Arrives

DexCom's G7 15-Day sensor transition cut manufacturing costs, lifting Q2 2026 gross margin by 400 bps to 64.1% and enabling 70% incremental operating margins as it targets non-insulin Type 2 diabetes ...
Stock News•2 weeks ago

Sana Biotechnology: A Shot At Diabetes

Sana Biotechnology trades at a steep discount despite early UP421 data showing durable insulin production without immunosuppression in type 1 diabetes. Cash runway is limited to 5 quarters at the curr...
Stock News•2 months ago

Xeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy Opportunity

Xeris Biopharma reported record 2024 revenues of $203M, up 24%, and guided 2025 revenue to $255M–$275M, implying ~30% growth at midpoint. XP-8121, a once-weekly levothyroxine, targets a $1B+ U.S. mark...

Breaking News

View All →

Top Headlines

View More →
Stock News•59 minutes ago

Jim Cramer sees major implications from SK Hynix's home-run quarter

Stock News•1 hour ago

Google parent Alphabet tumbles after profit disappoints, warns AI is battering its cash flow

Stock News•1 hour ago

Jim Cramer says these tech giants can weather market turbulence

Stock News•1 hour ago

Alphabet Inc. (GOOG) Misses Q3 Earnings and Revenue Estimates

Stock News•1 hour ago

Alphabet (GOOGL) Q3 Earnings and Revenues Miss Estimates